Andrey Zarur - Feb 2, 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC (GRNA)

Role
President & CEO, Director
Signature
/s/ David Kennedy, Attorney-in-fact
Stock symbol
GRNA
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 06:26 PM
Next filing
Jul 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GRNA Common Stock Award +896K 896K Feb 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +70.3K 70.3K Feb 2, 2022 Common Stock 70.3K $0.35 Direct F2, F3
transaction GRNA Stock Option (Right to Buy) Award +926K 926K Feb 2, 2022 Common Stock 926K $0.33 Direct F3, F4
transaction GRNA Stock Option (Right to Buy) Award +1.98M 1.98M Feb 2, 2022 Common Stock 1.98M $0.50 Direct F3, F5
transaction GRNA Stock Option (Right to Buy) Award +669K 669K Feb 2, 2022 Common Stock 669K $0.50 Direct F3, F6
transaction GRNA Stock Option (Right to Buy) Award +1.91M 1.91M Feb 2, 2022 Common Stock 1.91M $0.98 Direct F3, F7
transaction GRNA Stock Option (Right to Buy) Award +293K 293K Feb 2, 2022 Common Stock 293K $0.98 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for capital stock previously issued by such company.
F2 100% of the shares subject to this option are fully vested and exercisable.
F3 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F4 20% of the shares underlying the option vested or shall vest on September 12, 2018 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 12, 2018.
F5 20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting December 5, 2021.
F6 20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting December 5, 2021.
F7 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.
F8 25% of the shares underlying the option vested or shall vest after one year of service and the remainder of the shares vested or shall vest in 36 equal monthly installments.